scholarly journals MP34-19 EFFECT OF HISTOLOGICAL VARIANTS ON THE OUTCOMES OF RADICAL CYSTECTOMY FOR NON-METASTATIC MUSCLE-INVASIVE URINARY BLADDER CANCER

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Malte W. Vetterlein ◽  
Thomas Seisen ◽  
Jeffrey J. Leow ◽  
Mark A. Preston ◽  
Maxine Sun ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Radical Cystectomy ◽  
Urinary Bladder Cancer ◽  
Histological Variants ◽  
Muscle Invasive

Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy

2007 ◽  
Vol 40 (2) ◽  
pp. 321-327 ◽  
Author(s):  
Surendra B. Kolla ◽  
Amlesh Seth ◽  
Manoj K. Singh ◽  
Narmada P. Gupta ◽  
Ashok K. Hemal ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Radical Cystectomy ◽  
Prognostic Significance ◽  
Urinary Bladder Cancer ◽  
Muscle Invasive

Effective and less toxic trimodality approach in muscle invasive urinary bladder cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15505-e15505
Author(s):  
Reham Abdel-Wahab ◽  
Ahmed M. Eltaher ◽  
Hoda H. Essa ◽  
Samir-Shehata M. Eid
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Radical Cystectomy ◽  
Past History ◽  
Urinary Bladder Cancer ◽  
Bladder Capacity ◽  
Complete Response ◽  
Intravesical Therapy ◽  
Investigation Methods ◽  
Muscle Invasive

e15505 Background: Bladder cancer represents a global health problem. Radical cystectomy considered the standard of care for invasive bladder cancer. Because of the potential morbidity with surgery, organ preservation via trimodality approach has been the subject of investigation. The concurrent use of cisplatin with 5-FU or gemcitabin with local radiotherapy has been studied and the results were better than radical cystectomy. However, this was associated with grade 3-4 (G3-4) toxicity. Recently, similarly effective but less toxic regimen by the use of paclitaxel and cisplatin is under investigation. Methods: We proposed a single-center, single arm, phase II prospective cohort study. 30 patients (22 male and 8 female) with T2-T3 bladder cancer according to the AJCC 2010 were included. All patients were >18y with exclusion of those with bladder capacity < 350cc, hydronephrosis, with previous intravesical therapy, systemic chemotherapy or pelvic radiation, those currently receiving nephrotoxic or ototoxic drugs, and those with other malignancies. All patients treated with maximum transurethral resection (TUR) followed by local radiotherapy 64Gy concurrently with weekly 60mg/m2 Paclitaxel and 20mg/m2 Cisplatin. Results: Cystoscopic re-evaluation 6-8 weeks after the end of treatment revealed that 90% of patients achieve complete response (CR), 6.7% achieve partial response (PR) and 3.3% had stable disease (SD). Mild toxicity was infrequent and easily controlled without interruption of treatment except in one patient. Toxicity was in the form of cystitis G1 in 46.7% and G2 in 3.3%. Diarrhea G1 in 33.3% and G2 in 3.3%. Only one patient who has past history of piles, developed G2 proctitis that leads to irregularity of treatment. Other mild toxicities were: G1 dermatitis (80%), G1 bleeding per rectum (3.3%), G1 anemia (13.3%), G1 and G2 nausea and vomiting (50% and 33.3% respectively), while neutropenia and thrompocytopenia were not seen. Conclusions: Our preliminary results revealed that weekly low dose paclitaxel and cisplatin concurrently with local radiotherapy was effective, tolerable and has acceptable toxicity in the treatment of muscle invasive urinary bladder cancer.

Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer

2018 ◽  
Vol 16 (1) ◽  
pp. e129-e139 ◽  
Author(s):  
Malte W. Vetterlein ◽  
Thomas Seisen ◽  
Jeffrey J. Leow ◽  
Mark A. Preston ◽  
Maxine Sun ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Radical Cystectomy ◽  
Urinary Bladder Cancer ◽  
Muscle Invasive

scholarly journals Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer

2019 ◽  
Vol 20 (6) ◽  
pp. 1291 ◽  
Author(s):  
Aikaterini Giannopoulou ◽  
Athanassios Velentzas ◽  
Eumorphia Konstantakou ◽  
Margaritis Avgeris ◽  
Stamatia Katarachia ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Urinary Bladder ◽  
Histone Deacetylases ◽  
Strong Association ◽  
Hdac Inhibitors ◽  
Urinary Bladder Cancer ◽  
Molecular Heterogeneity ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder ◽  
Muscle Invasive

Urinary bladder cancer is a common malignancy, being characterized by substantial patient mortality and management cost. Its high somatic-mutation frequency and molecular heterogeneity usually renders tumors refractory to the applied regimens. Hitherto, methotrexate-vinblastine-adriamycin-cisplatin and gemcitabine-cisplatin represent the backbone of systemic chemotherapy. However, despite the initial chemosensitivity, the majority of treated patients will eventually develop chemoresistance, which severely reduces their survival expectancy. Since chromatin regulation genes are more frequently mutated in muscle-invasive bladder cancer, as compared to other epithelial tumors, targeted therapies against chromatin aberrations in chemoresistant clones may prove beneficial for the disease. “Acetyl-chromatin” homeostasis is regulated by the opposing functions of histone acetyltransferases (HATs) and histone deacetylases (HDACs). The HDAC/SIRT (super-)family contains 18 members, which are divided in five classes, with each family member being differentially expressed in normal urinary bladder tissues. Since a strong association between irregular HDAC expression/activity and tumorigenesis has been previously demonstrated, we herein attempt to review the accumulated published evidences that implicate HDACs/SIRTs as critical regulators in urothelial bladder cancer. Moreover, the most extensively investigated HDAC inhibitors (HDACis) are also analyzed, and the respective clinical trials are also described. Interestingly, it seems that HDACis should be preferably used in drug-combination therapeutic schemes, including radiation.

scholarly journals Squamous Cell Carcinoma of the Urinary Bladder: Clinicopathological and Molecular Update

2021 ◽  
Author(s):  
Sunil Vitthalrao Jagtap ◽  
Swati S Jagtap ◽  
Parneet Kaur ◽  
Snigdha Vartak
Keyword(s):  
Squamous Cell Carcinoma ◽  
Bladder Cancer ◽  
Urinary Bladder ◽  
Urothelial Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Urinary Bladder Cancer ◽  
Cell Phenotype ◽  
Molecular Features ◽  
Muscle Invasive

Urinary bladder cancer is one of the most prevalent cancers worldwide.Squamous Cell Carcinoma (SCC) is an uncommon subtype of urinary bladder carcinoma.It is a malignant epithelial neoplasm arising in the urinary bladder demonstrating a pure squamous cell phenotype. On histopathology it is considered when tumor is showing pure squamous morphology without any component of conventional urothelial carcinoma. The SCC is a histologically distinct form of cancer. It arises from the uncontrolled multiplication of cells showing particular cytological or tissue architectural characteristics of squamous cell differentiation, such as the presence of keratin, tonofilament bundles or desmosomes. Majority of bladder SCC are high grade, high stage tumors with most cancers having muscle invasion at the time of diagnosis while overall about 80% of bladder cancers are non-muscle invasive bladder cancer at diagnosis.COX-2 is markedly expressed in all SCCs. An increased COX-2 level induces the development of SCC of the bladder affecting many biological features of this tissue including apoptosis, cell adhesion, angiogenesis and invasiveness.TERT promoter mutations, commonly found in conventional urothelial carcinoma, are also highly prevalent in urinary bladder squamous cell carcinoma suggesting a common tumorgenesis and potential utility as a molecular urine-based-screening assay.This review summarizes the current features related to clinical , pathological, and molecular features of SCC of urinary bladder.

Sign in / Sign up

Export Citation Format

Share Document